Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Head and Neck Neoplasms 6Neoplasms, Squamous Cell 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × zalutumumab × Clear all
NCT00460551 2011-12-06

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Genmab

Phase 2 Terminated
13 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01449357 2011-10-10

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Genmab

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡